benzoyl peroxide; clindamycin phosphate · Bausch · NDA 050819

Onexton

Earliest generic entry, as listed
5 Aug 2029

Blocked by patent: US 8288434.

Listed patents · 5 unexpired

13 Orange Book listing rows for 5 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 8288434drug product, use U-1033, U-124, U-134, U-818, U-916, U-9215 Aug 2029
US 8288434 listing rowdrug product, use U-1033 · sets the listed date5 Aug 2029
US 8288434 listing rowdrug product, use U-124 · sets the listed date5 Aug 2029
US 8288434 listing rowdrug product, use U-134 · sets the listed date5 Aug 2029
US 8288434 listing rowdrug product, use U-818 · sets the listed date5 Aug 2029
US 8288434 listing rowdrug product, use U-916 · sets the listed date5 Aug 2029
US 8288434 listing rowdrug product, use U-921 · sets the listed date5 Aug 2029
US 10137142drug product, use U-9163 Jun 2029
US 10220049drug product, use U-9163 Jun 2029
US 9504704drug product, use U-124, U-134, U-818, U-9163 Jun 2029
US 9504704 listing rowdrug product, use U-1243 Jun 2029
US 9504704 listing rowdrug product, use U-1343 Jun 2029
US 9504704 listing rowdrug product, use U-8183 Jun 2029
US 9504704 listing rowdrug product, use U-9163 Jun 2029
US 9561208drug product, use U-9163 Jun 2029

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
050819 · 002 · RLDgel, topical3.75%;EQ 1.2% BASE5 Aug 2029